Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Clovis Oncology Inc (NASDAQ: CLVS) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Clovis Oncology Inc (NASDAQ: CLVS)  concerning whether a series of statements by Clovis Oncology Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On November 16, 2015, Clovis Oncology Inc announced that potential approval of rociletinib, a lung cancer treatment, will probably be delayed due to FDA requesting more data with regard to the use of two different dosages and their response rates.

On this news, Clovis Oncology Inc shares fell $69.19 or over 69% to close at $30.24 on November 16, 2015.

Based in Boulder, Colorado, and founded in 2009 Clovis Oncology Inc is a biopharmaceutical company focused on developing and commercializing cancer treatments in the United States and internationally.

If you purchased shares of Clovis Oncology Inc (NASDAQ: CLVS) on or before November 16, 2015, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185